Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). (Q45187274)
Jump to navigation
Jump to search
scientific article published in January 2005
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). |
scientific article published in January 2005 |
Statements
1 reference
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). (English)
1 reference
R Gervais
1 reference
A Ducolone
1 reference
J-L Breton
1 reference
D Braun
1 reference
B Lebeau
1 reference
F Vaylet
1 reference
D Debieuvre
1 reference
J-L Pujol
1 reference
J Tredaniel
1 reference
P Clouet
1 reference
E Quoix
1 reference
1 January 2005
1 reference
1 reference
Identifiers
1 reference